469 related articles for article (PubMed ID: 25772231)
1. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
Sieb JP; Themann P; Warnecke T; Lauterbach T; Berkels R; Grieger F; Lorenzl S
Curr Med Res Opin; 2015 May; 31(5):967-74. PubMed ID: 25772231
[TBL] [Abstract][Full Text] [Related]
2. Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson's disease.
Hirano M; Isono C; Fukuda K; Ueno S; Nakamura Y; Kusunoki S
J Neurol Sci; 2019 Sep; 404():5-10. PubMed ID: 31323520
[TBL] [Abstract][Full Text] [Related]
3. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
Sanford M; Scott LJ
CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211
[TBL] [Abstract][Full Text] [Related]
4. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L
BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880
[TBL] [Abstract][Full Text] [Related]
6. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
Perez-Lloret S; Rey MV; Ratti PL; Rascol O
Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
[TBL] [Abstract][Full Text] [Related]
7. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
Ceballos-Baumann A; Häck HJ
Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
[TBL] [Abstract][Full Text] [Related]
8. Rotigotine Transdermal Patch: A Review in Parkinson's Disease.
Frampton JE
CNS Drugs; 2019 Jul; 33(7):707-718. PubMed ID: 31243728
[TBL] [Abstract][Full Text] [Related]
9. Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders.
Antonini A; Bernardi L; Calandrella D; Mancini F; Plebani M
Funct Neurol; 2010; 25(1):21-5. PubMed ID: 20626993
[TBL] [Abstract][Full Text] [Related]
10. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
Kim JM; Chung SJ; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
BMC Neurol; 2015 Feb; 15():17. PubMed ID: 25879416
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on rotigotine in Parkinson's disease.
Baldwin CM; Keating GM
Drugs Aging; 2008; 25(2):175-7. PubMed ID: 18257604
[TBL] [Abstract][Full Text] [Related]
12. Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional study.
Timmermann L; Oehlwein C; Ransmayr G; Fröhlich H; Will E; Schroeder H; Lauterbach T; Bauer L; Kassubek J
Postgrad Med; 2017 Jan; 129(1):46-54. PubMed ID: 27883297
[TBL] [Abstract][Full Text] [Related]
13. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
Baldwin CM; Keating GM
CNS Drugs; 2007; 21(12):1039-55. PubMed ID: 18020483
[TBL] [Abstract][Full Text] [Related]
14. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
Boroojerdi B; Wolff HM; Braun M; Scheller DK
Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
[TBL] [Abstract][Full Text] [Related]
15. Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial.
Woitalla D; Kassubek J; Timmermann L; Lauterbach T; Berkels R; Grieger F; Müller T
Parkinsonism Relat Disord; 2015 Mar; 21(3):199-204. PubMed ID: 25595315
[TBL] [Abstract][Full Text] [Related]
16. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
[TBL] [Abstract][Full Text] [Related]
17. Rotigotine transdermal system for the treatment of Parkinson's disease.
Pham DQ; Nogid A
Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
[TBL] [Abstract][Full Text] [Related]
18. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
Zareba G
Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
[TBL] [Abstract][Full Text] [Related]
19. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain.
Rascol O; Zesiewicz T; Chaudhuri KR; Asgharnejad M; Surmann E; Dohin E; Nilius S; Bauer L
J Clin Pharmacol; 2016 Jul; 56(7):852-61. PubMed ID: 26626320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]